DK1969003T3 - Anvendelser af et neurotrofisk faktor-protein - Google Patents

Anvendelser af et neurotrofisk faktor-protein

Info

Publication number
DK1969003T3
DK1969003T3 DK05817611T DK05817611T DK1969003T3 DK 1969003 T3 DK1969003 T3 DK 1969003T3 DK 05817611 T DK05817611 T DK 05817611T DK 05817611 T DK05817611 T DK 05817611T DK 1969003 T3 DK1969003 T3 DK 1969003T3
Authority
DK
Denmark
Prior art keywords
applications
neurotrophic factor
factor protein
disease
patient
Prior art date
Application number
DK05817611T
Other languages
English (en)
Inventor
Mart Saarma
Juha Lauren
Paeivi Lindholm
Tonis Timmusk
Raimo Tuominen
Original Assignee
Hermo Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hermo Pharma Ltd filed Critical Hermo Pharma Ltd
Application granted granted Critical
Publication of DK1969003T3 publication Critical patent/DK1969003T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
DK05817611T 2005-12-14 2005-12-14 Anvendelser af et neurotrofisk faktor-protein DK1969003T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/FI2005/050461 WO2007068784A1 (en) 2005-12-14 2005-12-14 Novel neurotrophic factor protein and uses thereof

Publications (1)

Publication Number Publication Date
DK1969003T3 true DK1969003T3 (da) 2010-12-13

Family

ID=38162600

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05817611T DK1969003T3 (da) 2005-12-14 2005-12-14 Anvendelser af et neurotrofisk faktor-protein

Country Status (11)

Country Link
US (4) US20100285045A1 (da)
EP (2) EP1969003B8 (da)
JP (1) JP5236488B2 (da)
AT (1) ATE480559T1 (da)
AU (1) AU2005339101B2 (da)
CA (1) CA2633468C (da)
DE (1) DE602005023550D1 (da)
DK (1) DK1969003T3 (da)
ES (1) ES2352205T3 (da)
PL (1) PL1969003T3 (da)
WO (2) WO2007068784A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
EA201400002A1 (ru) * 2011-06-09 2014-08-29 Юниверсити Оф Майами Способы лечения заболеваний сетчатки
FI20115870A0 (fi) * 2011-09-05 2011-09-05 Urmas Arumaee Neuroprotektiiviset soluihin tunkeutuvat peptidit
US20130331330A1 (en) * 2012-06-08 2013-12-12 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating alzheimer's disease and other tauopathies with inhibitors of microtubule affinity regulating kinase
JP6495270B2 (ja) 2013-10-30 2019-04-03 ザ ユニバーシティ オブ ウェスタン オーストラリア 神経保護ペプチドを含有する医薬組成物
US20170252403A1 (en) * 2014-10-06 2017-09-07 Amarantus Bioscience Holdings, Inc. Methods and compositions for treating retinal disorders
EP3377089B1 (en) 2015-11-18 2020-04-08 Herantis Pharma Plc Compositions comprising cdnf for use in the intranasal treatment of central nervous system diseases
WO2018202957A1 (en) 2017-05-04 2018-11-08 Helsingin Yliopisto C-terminal cdnf and manf fragments, pharmaceutical compositions comprising same and uses thereof
CA3065423A1 (en) * 2017-06-02 2018-12-06 Peter Dominiek Emiel Maria VERHAERT Mass spectrometry histochemistry of peptides from formaldehyde-fixed, paraffin-embedded tissue
EP4678236A3 (en) 2018-03-29 2026-04-08 MyNeuroCure Oy C-terminal cdnf and manf fragments, pharmaceutical compositions comprising same and uses thereof
CN108925783B (zh) * 2018-07-23 2021-09-21 浙江大学 烟粉虱manf基因或其表达的蛋白作为靶点在制备防治烟粉虱的药物中的应用
EP3838345A1 (en) 2019-12-20 2021-06-23 Herantis Pharma Oyj Macrocyclic peptides
EP3838912A1 (en) 2019-12-20 2021-06-23 Herantis Pharma Oyj Retro-inverso peptides
US20260027182A1 (en) * 2022-04-21 2026-01-29 Instituto de Medicina Molecular João Lobo Antunes Mesencephalic astrocyte-derived neurotrophic factor (manf) for increasing muscle regeneration

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
DE3483949D1 (de) 1983-09-26 1991-02-21 Udo Dr Med Ehrenfeld Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
WO1991010470A1 (en) 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5328688A (en) 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US5849571A (en) 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
US6071889A (en) 1991-07-08 2000-06-06 Neurospheres Holdings Ltd. In vivo genetic modification of growth factor-responsive neural precursor cells
AU679167B2 (en) * 1991-09-20 1997-06-26 Amgen, Inc. Glial derived neurotrophic factor
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5879934A (en) 1992-07-31 1999-03-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US5661033A (en) 1992-11-25 1997-08-26 The Board Of Trustees Of The Leland Stanford Junior University Gene transfer using herpes virus vectors as a tool for neuroprotection
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
WO1994017810A1 (en) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
DE4311651A1 (de) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
EP0708658A4 (en) 1993-04-16 1997-05-21 Wistar Inst RECOMBINANT CYTOMEGALOVIRUS VACCINE
WO1995005864A1 (en) 1993-08-27 1995-03-02 Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Convection-enhanced drug delivery
US5834441A (en) 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
WO1995013365A1 (en) 1993-11-09 1995-05-18 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
FR2716682B1 (fr) 1994-01-28 1996-04-26 Centre Nat Rech Scient Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations.
US5686278A (en) 1994-03-25 1997-11-11 Indiana University Foundation Methods for enhanced retrovirus-mediated gene transfer
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US5792453A (en) 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
FR2732357B1 (fr) 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
US5830725A (en) 1995-04-28 1998-11-03 The Board Of Trustees For The Leland Stanford Junior University Rapid, stable high-titre production of recombing retrovirus
US5773289A (en) 1995-06-06 1998-06-30 University Of Pittsburgh AAV directed targeted integration
US6027931A (en) 1995-08-03 2000-02-22 Avigen, Inc. High-efficiency AA V helper functions
US5622856A (en) 1995-08-03 1997-04-22 Avigen High efficiency helper system for AAV vector production
US5830727A (en) 1995-11-18 1998-11-03 Human Gene Therapy Research Institute Herpes simplex virus amplicon mini-vector gene transfer system
US5770414A (en) 1996-02-20 1998-06-23 The Regents Of The University Of California Regulatable retrovirus system for genetic modification of cells
WO1999061066A2 (en) 1998-05-27 1999-12-02 Avigen, Inc. Convection-enhanced delivery of aav vectors
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
CA2383076A1 (en) 1999-09-16 2001-03-22 Neurotrophic Bioscience, Inc. Dopaminergic neuronal survival-promoting factors and uses thereof
WO2001055301A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2001054472A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20020132978A1 (en) 2000-03-21 2002-09-19 Hans-Peter Gerber VEGF-modulated genes and methods employing them
EP1368468A4 (en) * 2001-02-23 2005-02-16 Human Genome Sciences Inc HUMAN SEMINAR PROTEINS
US20040053250A1 (en) * 2001-03-05 2004-03-18 Tang Y. Tom Novel arginine-rich protein-like nucleic acids and polypeptides
US6783969B1 (en) * 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
WO2002074956A2 (en) * 2001-03-20 2002-09-26 Prescient Neuropharma Inc. Dopaminergic neuronal survival-promoting factors and uses thereof
CA2441327A1 (en) * 2001-03-30 2002-10-10 Geneprot, Inc. Human arginine-rich protein-related compositions
GB0113657D0 (en) 2001-06-05 2001-07-25 Geneprot Inc Improved native chemical ligation with three or more components
US20060195915A1 (en) * 2002-08-30 2006-08-31 Licentia Ltd. Novel neurotrophic factor protein and uses thereof
US7452969B2 (en) * 2002-08-30 2008-11-18 Licentia Ltd Neurotrophic factor protein and uses thereof

Also Published As

Publication number Publication date
EP1969003B1 (en) 2010-09-08
US20190153052A1 (en) 2019-05-23
EP1960426A1 (en) 2008-08-27
US9127082B2 (en) 2015-09-08
EP1969003A4 (en) 2009-03-25
EP1960426A4 (en) 2009-07-08
JP5236488B2 (ja) 2013-07-17
DE602005023550D1 (de) 2010-10-21
JP2009519028A (ja) 2009-05-14
AU2005339101B2 (en) 2013-01-10
ES2352205T3 (es) 2011-02-16
WO2007068803A1 (en) 2007-06-21
US20100285045A1 (en) 2010-11-11
AU2005339101A1 (en) 2007-06-21
US20110251132A1 (en) 2011-10-13
EP1960426B1 (en) 2014-04-02
EP1969003B8 (en) 2010-11-10
CA2633468A1 (en) 2007-06-21
US20080269154A1 (en) 2008-10-30
CA2633468C (en) 2014-02-18
PL1969003T3 (pl) 2011-05-31
ATE480559T1 (de) 2010-09-15
EP1969003A1 (en) 2008-09-17
WO2007068784A1 (en) 2007-06-21
US8980821B2 (en) 2015-03-17

Similar Documents

Publication Publication Date Title
DK1969003T3 (da) Anvendelser af et neurotrofisk faktor-protein
NZ595063A (en) Polypeptides from neisseria meningitidis
PE20100684A1 (es) Anticuerpo anti b-4-amiloide que contiene asparagina glicosilada en la region variable de vh
NZ621196A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
TW200602071A (en) Methods for preventing and treating alzheimer's disease (ad)
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
BRPI0813699A2 (pt) Formulações de proteína de fusão glp-1-fc
BR0208150A (pt) Antagonistas de mch e sua aplicação no tratamento da obesidade
DE602006002726D1 (de) Vorrichtung und verfahren zur behandlung von dermatomykosen und insbesondere onychomykosen
UA116871C2 (uk) СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII
BR0315157A (pt) Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
UA102061C2 (ru) Агонистическое антитело к notch3 и его применение для лечения notch3- ассоциированных заболеваний
EP1505990A4 (en) METHOD FOR THE TREATMENT OF HEPATITIS
MX2010006211A (es) Proteínas elastasa recombinantes y métodos de fabricación y uso de las mismas.
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
BR0307627A (pt) Métodos e composições para o tratamento de doenças do olho
EP2114431A4 (en) COMPOSITION WITH ARAZYM FOR THE PREVENTION AND TREATMENT OF CANCER
BR0214363A (pt) Anticorpo, uso de um anticorpo, medicamento, método de fabricação de um medicamento e pacote farmacêutico para o tratamento de infecção
WO2004043373A3 (en) Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
ATE552271T1 (de) Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon
EP1534753A4 (en) ANTIBODY PEG POSITION SISOMERS, COMPOSITIONS CONTAINING THEM AND USE THEREOF
ATE554793T1 (de) Konjugat
NZ591738A (en) Non-typhoidal salmonella vaccines comprising a polypeptide which is an outer membrane protein d of non typoidal salmonella
ATE420890T1 (de) Isoleucyl-valyl-threonyl-asparaginyl-threonyl- threonin (ivtntt) enthaltende biologisch wirksame peptide